📰 Myeloma Program News
Page 3 - Myeloma Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Myeloma Program. Real-time updates on events, politics, business and more.
June 10, 2023
The combination of the BCMA- and GPRC5D-targeted bispecific antibodies, teclistamab and talquetamab, respectively, demonstrated encouraging overall response rates and was well tolerated in patients with relapsed or refractory multiple myeloma.
June 4, 2023
Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.
April 18, 2023
New Blood Cancer Therapy Gives a New Lease on Life To 73% of Patients - Industry Tap
December 12, 2022
A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
December 10, 2022
An antibody infusion could be a game changer for people with persistent multiple myeloma, an aggressive blood cancer. The therapy was successful about 73 per cent of the time.
December 10, 2022
Get latest articles and stories on Health at LatestLY. The treatment, which is referred to as a "bispecific antibody," binds to both T cells and multiple myeloma cells and instructs the T cells, which are white blood cells that can be used to fight off diseases Health News | Experimental Cancer Therapy Shows 73 Pc Success Rate in Trials: Study.
December 9, 2022
/PRNewswire/ -- Tampa General Hospital is announcing its appointment of Dr. Ivan Borrello to the TGH Cancer Institute. Borrello is a world-class translational...
August 28, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...
August 27, 2022
Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharm
August 27, 2022
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...